#USA #Hamilton #Actinium-225 #AtomVie #TerraPower Isotopes

AtomVie Partners with TerraPower for Actinium-225 Supply

In a significant development within the radiopharmaceutical industry, AtomVie Global Radiopharma (AtomVie) has announced a strategic supply agreement with TerraPower Isotopes, LLC (TPI) aimed at enhancing the production and development of radiopharmaceuticals. This collaboration focuses specifically on Actinium-225 (Ac-225), a critical isotope required for targeted therapy in cancer treatment.

AtomVie, a prominent Contract Development and Manufacturing Organization (CDMO), aims to utilize TPI's high-quality Ac-225 to bolster its capabilities in the radiopharmaceutical sector. By securing a reliable supply of this isotope, AtomVie seeks to meet the evolving needs of its pharmaceutical partners more effectively, thereby ensuring a steady and responsive development process from early research to commercial availability.

Strengthening the Supply Chain

The newly established supply agreement represents a crucial step in fortifying the supply chain of radiopharmaceuticals. By guaranteeing a consistent source of Ac-225, both companies intend to increase the flexibility and rapidity of response throughout the product development lifecycle. The collaboration is expected to facilitate various early and late-stage development programs with global pharmaceutical partners, ultimately enhancing the speed at which new and effective cancer treatment solutions can reach the market.

Bruno Paquin, the CEO of AtomVie, expressed enthusiasm about this partnership, stating, "We are excited to work with TerraPower Isotopes to ensure the supply of Actinium-225 for our clients. This strengthens our ability to fulfill the changing needs of our pharmaceutical partners by supporting their programs from development to commercial release. Together, we are advancing innovative therapies and improving patients' lives worldwide with high-quality radiopharmaceuticals."

On the other hand, Scott Claunch, the President of TerraPower Isotopes, noted, "By collaborating with AtomVie, we can advance the next generation of targeted radiopharmaceutical therapies. By combining our access to extremely pure Ac-225 with their development and manufacturing capabilities, we are proud to play a critical role in spreading therapies that have the potential to improve patient outcomes."

The Role of Actinium-225 in Cancer Therapy

Actinium-225 is particularly significant due to its potential in treating various types of cancer. In radiopharmaceutical therapy, Ac-225 is utilized for its alpha-emitting capability, which allows for precise targeting of cancer cells while minimizing damage to surrounding healthy tissues. This specificity positions Ac-225 as a vital tool in the fight against cancer, enabling more effective treatments with potentially fewer side effects.

The strategic alliance between AtomVie and TPI reflects their shared commitment to advancing nuclear medicine innovations and expanding global access to state-of-the-art radiation therapies. With the landscape of cancer treatment continually evolving, this partnership is timely and critical, promising to unlock new possibilities for patients and healthcare providers alike.

In addition to enhancing the production capabilities for Ac-225, this agreement also highlights AtomVie's ongoing expansion efforts, including the construction of a new state-of-the-art facility slated for completion in late 2025. This facility aims to bolster AtomVie’s infrastructure for the development and distribution of clinical and commercial radiopharmaceuticals, further solidifying its position as a leader in the industry.

For those interested in the future of cancer therapy and nuclear medicine, the partnership between AtomVie and TerraPower Isotopes is a development worth following closely. This collaboration not only promises to enhance the supply of Actinium-225 but also embodies the ongoing commitment to innovating and improving treatment outcomes for patients worldwide.